Skip to main content
Equibles

CLLS · Cellectis S.A. · Webcasts, Transcripts & Audio

Track CLLS — free

Use CLLS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CLLS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.41 -0.02 (-1.40%) At close · Oct 5
Rebalance outlook locked
Market Cap
$151.08M
Shares
100.72M
Volume · Oct 5 37.27K Avg daily vol (3M) 76.2K

Cellectis S.A. Webcasts

Earnings calls, investor updates, investor days and conferences for Cellectis S.A. (CLLS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲151.7% $2.90M −$32.26M '20 Q2 20-06-30 ▼88.3% $1.31M −$18.95M '22 Q2 22-06-30 ▲53.1% $2.00M −$11.37M '23 Q2 23-06-30 LATEST ▲107.5% $16.73M −$23.74M '25 Q2 25-06-30
Conference
Investor event
2026-11-17
Cellectis S.A. (CLLS) November 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
Cellectis S.A. (CLLS) November 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Cellectis S.A. (CLLS) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-08
Cellectis S.A. (CLLS) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Cellectis S.A. (CLLS) Q2 2026 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Annual General Meeting
Investor event
2026-06-25
Cellectis S.A. (CLLS) June 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio Transcript Slides
Annual General Meeting
Investor event
2026-06-25
Cellectis S.A. (CLLS) June 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-20
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
Confident tone Competitive landscape and in vivo CAR-T LASMICEL pivotal Phase 2 in B-ALL Manufacturing and lymphodepletion optimization
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-06-30
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript
Confident tone Servier / Allogene arbitration Regulatory interactions (FDA / EMA) Lasme-cel / UCART22 BALLI-01 in r/r B-ALL
Revenue
$16.73M
▲ 107.5% YoY
Diluted EPS
$-0.24
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
Confident tone AstraZeneca partnership and equity investment Competitive landscape and CARGO setback Allogeneic CAR T durability / ALLO-501A data
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
Confident tone BALLI-01 / UCART22 clinical trial AstraZeneca collaboration Phase II regulatory strategy
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript
Confident tone AstraZeneca partnership and equity investment BALLI-01 trial in ALL NatHaLi-01 trial in B-cell NHL
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-09-30
Cellectis S.A. (CLLS) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Cellectis S.A. (CLLS) Q2 2023 Earnings Call Transcript
Revenue
$2.00M
▲ 53.1% YoY
Diluted EPS
$-0.20
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Cellectis S.A. (CLLS) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Cellectis S.A. (CLLS) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Cellectis S.A. (CLLS) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Cellectis S.A. (CLLS) Q2 2022 Earnings Call Transcript
Revenue
$1.31M
▼ 88.3% YoY
Diluted EPS
$-0.42
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Cellectis S.A. (CLLS) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Cellectis S.A. (CLLS) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Cellectis S.A. (CLLS) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Cellectis S.A. (CLLS) Q2 2020 Earnings Call Transcript
Revenue
$2.90M
▲ 151.7% YoY
Diluted EPS
$-0.76
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Cellectis S.A. (CLLS) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–23 of 23 webcasts
Key facts CIK 1627281 CUSIP 15117K103 Visit website Investor relations